Manual Review Required

PD-L1 expression

gastric cancer · Immune Checkpoint Inhibitor

PD-L1 expression is flagged as manual review required because public trials show inclusion required evidence in 18 contexts. FDA CDx context exists. Threshold text varies across public records.

Back to report

Role evidence

Usage summary

Strongest role: Inclusion Required

Inclusion-required count: 11

Treatment-assignment count: 0

Stratification count: 0

Threshold snippets

Fragmentation view

Threshold count: 21

Common snippets: PD-L1 CPS ≥10 | PD-L1 CPS ≥1 | PD-L1 CPS ≥1

Threshold label: Fragmented

FDA CDx context

Mapping summary

CDx label: Fda Cdx Context Exists

CDx maturity score: 5/5

Confidence: Low

Patent-density signal

Diagnostic appendix

Signal count: 1

Recent signals: 1

Density label: Low

Source links

Evidence paths

https://clinicaltrials.gov/study/NCT03342937 | https://clinicaltrials.gov/study/NCT02494583 | https://clinicaltrials.gov/study/NCT03647969 | https://clinicaltrials.gov/study/NCT07432295 | https://clinicaltrials.gov/study/NCT03959293 | https://clinicaltrials.gov/study/NCT03488667 | https://clinicaltrials.gov/study/NCT05535569 | https://clinicaltrials.gov/study/NCT05544929 | https://clinicaltrials.gov/study/NCT02589496 | https://clinicaltrials.gov/study/NCT03407976 | https://clinicaltrials.gov/study/NCT03257163 | https://clinicaltrials.gov/study/NCT07542262 | https://clinicaltrials.gov/study/NCT04006262 | https://clinicaltrials.gov/study/NCT07673887 | https://clinicaltrials.gov/study/NCT07431281 | https://clinicaltrials.gov/study/NCT06901531 | https://clinicaltrials.gov/study/NCT07270991 | https://clinicaltrials.gov/study/NCT05365581